Hypodermic Insulin Syringe 0.3ml x 8mm 30G (100)

Becton Dickinson

Injection & Infusion

Insulin syringes (0.3ml, 30G x 8mm, fixed needle)

CE Marked Class IIa medical device under the Medical Devices Directive 93/42/EEC for insulin syringes.
Manufactured under an ISO 13485 Certified quality management system.
Designed and tested in accordance with ISO 8537 for sterile single Use syringes for insulin.
Sterilised by validated gamma radiation in compliance with EN 556 1, EN ISO 11137 and EN ISO 11737 standards.
Non Toxic, non Pyrogenic and latex Free, as declared in the manufacturer’s technical data sheet and declaration of conformity.

CE Marked Class IIa medical device under the Medical Devices Directive 93/42/EEC for insulin syringes.
Manufactured under an ISO 13485 Certified quality management system.
Designed and tested in accordance with ISO 8537 for sterile single Use syringes for insulin.
Sterilised by validated gamma radiation in compliance with EN 556 1, EN ISO 11137 and EN ISO 11737 standards.
Non Toxic, non Pyrogenic and latex Free, as declared in the manufacturer’s technical data sheet and declaration of conformity.

Insulin syringes (0.3ml, 30G x 8mm, fixed needle)

Description

The Hypodermic Insulin Syringe 0.3ml x 8mm 30G (100) is a box of 100 sterile, single-use BD Micro-Fine insulin syringes with an integrated 30G, 8mm needle and 0.3ml barrel. Designed for precise subcutaneous administration of U-100 insulin, the clear barrel and fine graduation scale support accurate dose measurement, while the sharp, ultra-thin-walled needle and silicone lubrication help promote a smoother, more comfortable injection. These fixed-needle syringes are non-toxic, non-pyrogenic, latex-free and supplied in polybags/boxes for professional clinical use or patient self-administration under medical supervision.

Bnefits

0.3ml U-100 insulin syringe with integrated 30G x 8mm needle for precise subcutaneous dosing.
Micro-fine, sharp-edged needle and ultra-thin walls designed to reduce tissue trauma and improve injection comfort.
Clear barrel and bold graduation marks to support accurate dose measurement and easy visual inspection for air bubbles.
Sterile, single-use, latex-free and non-pyrogenic construction for patient safety.
Fixed-needle design minimises dead space and helps to reduce medication waste.
Engineered to meet ISO 8537 requirements for sterile, single-use insulin syringes.
CE-marked Class IIa medical device with validated gamma sterilisation and documented quality control.
Supplied in boxes of 100 syringes, convenient for clinics, pharmacies, and trained patients on insulin therapy.

Indications

Subcutaneous administration of U-100 insulin for the treatment of diabetes mellitus, as prescribed by a healthcare professional.
Use by patients with diabetes who have been trained in self-injection techniques, or by healthcare professionals in clinical or home-care settings.
Situations where low-volume, fine control dosing (up to 0.3ml) of insulin or other compatible solutions is required, as directed by a clinician.

Composition

Cannula: Stainless steel.
Cannula lubricant: Silicone-based lubricant.
Barrel: Polypropylene.
Barrel lubricant: Silicone oil.
Hub (0.3ml syringe): Polypropylene.
Adhesive (needle bonding): Ultraviolet-curing adhesive.
Plunger rod: Polystyrene.
Stopper (piston): Polyisoprene (synthetic rubber, latex-free).
Needle shield: Polyethylene with colourant.
Plunger cap (where present on self-contained syringes): Polyethylene.
Product is latex-free, non-toxic and non-pyrogenic.

Formulation

Sterile, single-use insulin syringe with fixed (integrated) 30G x 8mm stainless steel needle.
0.3ml U-100 insulin capacity barrel with fine graduation scale for accurate dosing.
Self-contained sterile interior with protective needle shield prior to use.
Gamma-sterilised and supplied ready for immediate clinical use, without further preparation.
Designed and tested according to ISO 8537 for sterile single-use insulin syringes.

Packaging

Box of 100 BD Micro-Fine insulin syringes, 0.3ml with fixed 30G x 8mm needle.
Syringes supplied in internal polybags within the outer box (quantity per polybag as per manufacturer’s configuration).
Outer packaging clearly labelled with product identification, volume, needle gauge and length, batch/lot number, expiry date and CE marking.
Intended for professional clinical storage (pharmacies, clinics, hospitals) or controlled patient home use as instructed by a healthcare professional.

Usage

For subcutaneous injection only; use strictly as directed by a healthcare professional.
Check the packaging before use; do not use if the blister/outer pack is damaged, open or if the expiry date has passed.
Wash and dry hands and prepare the injection site according to local protocols (e.g. clean with appropriate skin disinfectant and allow to dry).
Remove the syringe from its packaging and carefully remove the needle shield without touching the needle to keep it sterile.
Draw up the prescribed dose of U-100 insulin following local technique and manufacturer’s instructions, ensuring there are no air bubbles and the dose marking is correct.
Pinch or otherwise prepare the skin at the recommended injection site, insert the 30G x 8mm needle subcutaneously at the angle advised by the prescriber or clinical guidelines.
Depress the plunger slowly and steadily to deliver the full dose, then wait briefly before withdrawing the needle to minimise leakage.
Dispose of the used syringe immediately into an approved sharps container; do not recap the needle after use and do not reuse the syringe.
Rotate injection sites as instructed by a healthcare professional to reduce the risk of lipodystrophy and local irritation.
Seek guidance from a healthcare professional regarding dose adjustment, injection technique and any concerns related to injection pain, bleeding, bruising or site reactions.

Contraindications

Do not use in patients with known hypersensitivity to any of the syringe component materials if clinically relevant (e.g. rare reactions to plastics, silicone oil or synthetic rubber).
Not suitable for intravenous administration or for use with medications that are not appropriate for subcutaneous injection via fine-gauge insulin syringes.
Do not use for administration of non-U-100 insulin formulations unless specifically confirmed as compatible by a healthcare professional.
Do not reuse; reuse of single-use syringes greatly increases the risk of infection, needle blockage, reduced sharpness and inaccurate dosing.

Adverse Effects

Local injection site reactions such as pain, redness, bruising, minor bleeding or swelling.
Potential for lipodystrophy or lipoatrophy at injection sites when injection-site rotation protocols are not followed (related to insulin therapy rather than the syringe itself).
Very rare risk of local skin or soft tissue infection if aseptic technique is not followed.
Discomfort or tissue trauma may occur if injection technique is poor or if the syringe is misused.
Allergic or sensitivity reactions to materials are rare but possible; discontinue use and seek medical advice if severe or persistent reactions occur.

Storage Conditions

Store syringes in their original packaging until use to maintain sterility.
No special storage conditions are required beyond normal dry, clean conditions; avoid excessive heat, freezing, or direct sunlight.
Keep away from sharp objects or crushing forces that could damage the syringe or needle.
Store out of the reach of children and unauthorised persons.
Observe the manufacturer-specified shelf life (typically 5 years from sterilisation) and do not use beyond the expiry date printed on the packaging.

Duration

Intended for repeated daily or periodic use over the course of long-term insulin therapy, with a new sterile syringe used for each injection. Each individual syringe is single-use only and should be discarded immediately after one injection.

Onset

The syringe itself has no pharmacological effect; onset and duration of effect depend on the insulin formulation used. When used correctly, it allows immediate administration of the prescribed insulin dose, with insulin onset following the pharmacokinetics of the specific insulin product.